Meet our partners and members
Founded by “entrepreneur of the year”, Sara Mangsbo as a spin-off from Uppsala University, Immuneed is a contract research organization specializing in immunology and preclinical drug development. Their platform is a unique and powerful alternative to preclinical testing and can reliably predict even slight safety risks. Thereby empowering clients to enter clinical trials with a drug that is correct and safe.
Transforming potential risks into vital insights
Given the growing number of biologics and immune-targeting drugs, the need to measure and predict the risk of adverse drug reactions in patients is urgent. Animal models fail to address questions related to both safety and effect – resulting in project delays, increased costs and, above all, a non-optimized clinical program with inherent risks for trial participants. With Immuneed’s help, you can obtain preliminary effect data and be more certain that your drug is safe enough to enter the human body. The overall goal is to provide meaningful insights that help clients enter clinical trials prepared.
From immunotherapy to service-platform
Immuneed was founded in 2014 and initially focused on the development of a novel immunotherapy for cancer. As the evaluation of this therapeutic vaccine grew more complex, they developed a proprietary platform to characterize the drug and predict outcomes in a clinical setting, thereby reducing animal studies and giving early indications of the effect in humans. In 2018, the vaccine project was acquired by the Norwegian pharmaceutical company Ultimovacs. Today they are fully focused on developing the platform and associated services, which benefit biotechnology and pharmaceutical companies across Europe.
What is unique with Immuneed’s platform is the opportunity to study blood-drug interactions in real-time. The simultaneous study of safety and function provide multiple read-outs from a single sample, thereby, cutting costs by as much as 40%.
“Immuneed’s platform is a unique and powerful alternative to traditional preclinical testing methods and we can reliably predict even slight safety risks. Thereby we empower our clients to enter clinical trials with a drug that is correct and safe”, explains Charlotte Leife, CEO of Immuneed.
How does the platform work?
Using circulating, fresh human blood, the platform provides a physiologically relevant testing environment. Unlike other preclinical testing methods, Immuneed’s platform leaves all blood components intact, from the plasma and cells to the complement proteins and endogenous antibodies. Likewise, the blood’s complement and coagulation cascade systems remain fully active, so that no response goes unmissed – even if they are unexpected.
Local strengths for global achievements
Immuneed was founded by Uppsala-based researcher and Sara Mangsbo, and the company is a spin-off from Uppsala University.
”Our vision is to serve customers across the globe in order to deliver safer drugs. To reach this we need to increase the awareness of our platform and effectively communicate the value”, explains Charlotte Leife. Recent investments were made into a new web page and automation tools to support their marketing strategy and strengthen their presence, awareness and outreach. Check out the new webpage here. “We value the great net-work in Uppsala’s life science cluster where you meet companies in similar areas with the same challenges and opportunities. We also value the support you get from Uppsala BIO”, finishes Charlotte Leife, CEO of Immuneed. The next collaboration with Uppsala BIO will be an “Efter Jobbet”, where Imunneed, together with Clinical Trial Consultants and RegSmart, will host a panel discussion where Sara Mangsbo, will moderate the insightful debate. The panel discussion will take place on January 14, 2020 at the Innovation Hub in Uppsala. (read more).
”We value the great net-work in Uppsala’s life science cluster where you meet companies in similar areas with the same challenges and opportunities. We also value the support you get from Uppsala BIO”, Charlotte Leife, CEO of Immuneed.